The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for Novartis Ilaris for use in acute gouty arthritis patients who are not suitable for current treatments. The only ...
Tags: Medicinal Products, therapies, treatments
Finland -based implantable medical devices manufacturer BonAlive Biomaterials has announced the signing of a multi-year exclusive distribution agreement with Olympus Biotech, a wholly owned company of Olympus Corporation focused on ...
Tags: BonAlive Biomaterials inks, medical devices, Olympus Biotech
The European Commission has issued clearance to market Novo Nordisk's diabetes therapies, Tresiba and Ryzodeg, across 27 European Union (EU) states. Novo Nordisk anticipates launching Tresiba, brand name of insulin degludec, in the UK and ...
Tags: Ryzodeg diabetes drugs, injection doses, diabetes therapies
Six translational health research centers across the globe have formed an alliance to advance the global international academic and/or not-for-profit drug development. The alliance will also focus on commercializing network, thereby ...
Teijin Pharma will launch Ipsen's Somatuline subcutaneous injection in 60mg, 90mg and 120mg doses, indicated to treat acromegaly and pituitary gigantism, in Japan. The medication is indicated for acromegaly and pituitary gigantism ...
Sanovas has filed Vas Zeppelin Smart Catheter's application with the US Food and Drug Administration (FDA) for approval. The miniaturized interventional catheter, which the company claims is the smallest interventional catheters ...
Tags: Sanovas, Vas Zeppelin Smart Catheter, FDA
Genoa Pharmaceuticals and McMaster University have partnered to characterize the in vivo advantages and potential clinical impact of Genoa's inhaled GP-101 (aerosol pirfenidone) for the treatment of idiopathic pulmonary fibrosis (IPF). ...
Tags: Pharmaceuticals, clinical impact, exploring mechanisms
Covidien has completed enrolling the first patient in SWIFT PRIME trial of its Solitaire FR Revascularisation device, designed to restore blood flow, administer medical therapy as well as retrieve clot in patients with acute ischemic ...
Tags: Covidien, patient, SWIFT PRIME trial
Healthcare products company Covidien has purchased California-based CV Ingenuity, which is focused on improving patient outcomes in the treatment of vascular diseases. CV Ingenuity's core technology Drug Coated Balloon (DCB), which ...
Tags: healthcare, Covidien, CV, DCB, purchase
Inovia Pharmaceuticals will move its hepatitis C DNA vaccine into a phase 1/11a clinical trial by the end of 2013. The advancement of this work is based on exceptional results of a preclinical study, which showed for the first time that a ...
Tags: Inovia Pharmaceuticals, hepatitis C DNA vaccine, clinical trial, 2013
Shire, a specialty biopharmaceutical company, is set to purchase US-based biotechnology company Lotus Tissue Repair. Under the purchase, Lotus Tissue Repair's intravenous protein replacement therapy, which is in late pre-clinical ...
Tags: Shire, biopharmaceutical company, US, Lotus Tissue Repair
Provectus Pharmaceuticals has announced the commencement of Phase 1 study of PV-10 injection to elucidate bystander effect at the Moffitt Cancer Center. The study is designed to assess the possible immune biomarkers in both tumor tissue ...
Tags: Provectus, injection, immune biomarkers, PV 10 injection
The US Patent and Trademark Office(USPTO)has awarded Patent No.8,341,015 to the OPTIMIZERx's SampleMD eCoupon technology. The patent protects claims related to the technology which has the ability to electronically process,display and ...
Tags: medications, therapies, OPTIMIZERx, SampleMD eCoupon technology
The analysis of DNA mutations in patients with cancer can be carried out without surgery. This is according to new research from AACC's Clinical Chemistry journal, which demonstrated that the plasma of cancer patients also includes ...
Tags: DNA mutations, cancer, surgery, Clinical Chemistry
Repligen has announced a new licensing agreement with Pfizer in an effort to advance Repligen's spinal muscular atrophy (SMA) program. The work focuses on RG3039, which is a small molecule drug candidate in clinical development for the ...
Tags: Repligen, Pfizer, spinal muscular atrophy, Medicine